Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
February 04 2022 - 8:00AM
Business Wire
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”)
announced today that the Company will release its fourth quarter
and full year 2021 financial results on Wednesday, March 2, 2022,
prior to market open. The Company will host a conference call and
live webcast with the investment community at 8:30 a.m. Eastern
Time on March 2, 2022.
The financial results and live webcast will be accessible
through the Investor Relations section of the Company's website at
https://investors.amneal.com.
To access the call through a conference line, dial (844)
200-6205 (in the U.S.) or (929) 526-1599 (international callers).
The access code for the call is 086998.
A replay of the conference call will be posted shortly after the
call and will be available for seven days. To access the replay,
dial (866) 813-9403 (in the U.S.) or +44 (204) 525-0658
(international callers). The access code for the replay is
311554.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in
Bridgewater, NJ, is a fully-integrated essential medicines company.
We make healthy possible through the development, manufacturing,
and distribution of generic and specialty pharmaceuticals,
primarily within the United States. The Company has a diverse
portfolio of approximately 250 products in its Generics segment and
is expanding across a broad range of complex products and
therapeutic areas, including injectables and biosimilars. In its
Specialty segment, Amneal has a growing portfolio of branded
pharmaceutical products focused primarily on central nervous system
and endocrine disorders, with a pipeline focused on unmet needs.
Through its AvKARE segment, the Company is a distributor of
pharmaceuticals and other products for the U.S. federal government,
retail, and institutional markets. For more, please visit
www.amneal.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220204005021/en/
Anthony DiMeo Senior Director, Investor Relations
Anthony.DiMeo@amneal.com
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024